Delving into the Latest Updates on WT-2725 with Synapse

Overview

Basic Info

Drug Type

Shared antigen vaccine, Therapeutic vaccine

Synonyms

Target

WT1

Mechanism

WT1 modulators(Wilms' Tumour 1 modulators)

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Hematologic Neoplasms

Inactive Indication

Advanced Malignant Solid Neoplasm

Originator Organization

Sunovion Pharmaceuticals Europe Ltd.

Active Organization

Osaka University

Sumitomo Pharma Co., Ltd.Sunovion Pharmaceuticals Europe Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

AbstractWT2725 is a Wilms’ tumor gene 1 (WT1)-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1+ tumors in human leukocyte antigen (HLA)-A*0201+ and/or HLA-A*0206+ patients. Here, we report the results of a phase I study of WT2725. In this phase I, open-label, dose-escalation and expansion two-part study, the WT2725 dosing emulsion was administered as a monotherapy to patients with advanced malignancies known to overexpress WT1, including glioblastoma. In part 1, 44 patients were sequentially allocated to four doses: 0.3 mg (n = 5), 0.9 mg (n = 5), 3 mg (n = 6), and 9 mg (n = 28). In part 2, 18 patients were allocated to two doses: 18 mg (n = 9) and 27 mg (n = 9). No dose-limiting toxicities were observed, so the maximum tolerated dose was not reached. Median progression-free survival was 58 (95% confidence interval [CI] 56–81) days (~ 2 months) across all patients with solid tumors; median overall survival was 394 days (13.0 months) (95% CI 309–648). Overall immune-related response rate in solid tumor patients was 7.5% (95% CI 2.6–19.9); response was most prominent in the glioblastoma subgroup. Overall, 62.3% of patients were considered cytotoxic T-lymphocyte responders; the proportion increased with increasing WT2725 dosing emulsion dose. WT2725 dosing emulsion was well tolerated. Preliminary tumor response and biological marker data suggest that WT2725 dosing emulsion may exert antitumor activity in malignancies known to overexpress the WT1 protein, particularly glioblastoma, and provide a rationale for future clinical development.Trial registration: NCT01621542.

100 Deals associated with WT-2725

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hematologic Neoplasms	Phase 1	-	Sunovion Pharmaceuticals Europe Ltd.	-
Hematologic Neoplasms	Phase 1	-	Sumitomo Pharma Co., Ltd.	-
Hematologic Neoplasms	Phase 1	-	Osaka University	-
Advanced Malignant Solid Neoplasm	Discovery	-	Sumitomo Pharma Co., Ltd.	01 Dec 2013
Neoplasms	Discovery	US	Sumitomo Pharma Co., Ltd.	31 Jul 2012
Hematologic Neoplasms	Discovery	US	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01621542 (CTgov)	Phase 1	Neoplasms	64	WT2725 (WT2725 0.3 mg)	hsvnqhyvza(nigricsaqv) = vsqclvtmfe skjshodegu (gzxlmvchcs, rhfsxckuax - yvpktbsdsi) View more	-	05 Apr 2019
NCT01621542 (CTgov)	Phase 1	Neoplasms	64	WT2725 (WT2725 0.9 mg)	hsvnqhyvza(nigricsaqv) = twfsxloebe skjshodegu (gzxlmvchcs, qqennydtfm - vvhupnbsgr) View more	-	05 Apr 2019
NCT01621542 (ASCO2017)	Phase 1	Advanced cancer	62	WT2725 0.3 mg	(uflkzkrktj) = kqugndpdvv vpvfdsxsrt (zwyxtzxfjm ) View more	-	30 May 2017